Testimony Before the FDA’s Antimicrobial Drugs Advisory Committee Regarding the Request for Emergency Use Authorization of Molnupiravir for Treatment of COVID-19
In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Antimicrobial Drugs Advisory Committee, Public Citizen argued that based on the available clinical and preclinical data for molnupiravir, there is significant uncertainty regarding whether the known and potential benefits of molnupiravir for treating COVID-19 at the proposed dosage outweigh the known and potential risks of the drug.
See Public Citizen’s other work on the COVID-19 pandemic.